Elusive sentinels at the Hodgkin checkpoint

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

(2020) Paul J. Bröckelmann et al.   JAMA Oncology

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

(2020) Fathima Zumla Cader et al.   NATURE MEDICINE

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

(2020) Sarah Reinke et al.   BLOOD

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

(2019) Justin Kline et al.   BLOOD

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

(2018) Frank Vari et al.   BLOOD

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

(2018) Max D. Wellenstein et al.   IMMUNITY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE